Table 4.
Tumor site and type in PARP-1−/− and PARP-1+/+ mice.
| Tumor localization and type | PARP-1+/+ | PARP-1−/− | |||
|---|---|---|---|---|---|
| Number of tumor-bearing mice (%) | Survival, days | Number of tumor-bearing mice (%) | Survival, days | ||
| Uterus | Sarcoma | 37 (36%) | 713 ± 21.0 | 28 (38%) | 659 ± 22.9 |
| Adenocarcinoma | 5 (5%) | 799 ± 41.2 | 5 (7%) | 709 ± 33.5 | |
| Hemangioma | 19 (18%) | 761 ± 29.9 | 1(1%)*** | 679 | |
| Hemangioendothelioma | 3 (3%) | 635 | 2 (3%) | 664 | |
| Polyp | 8 (8%) | 718 ± 65.6 | 2 (3%) | 601 | |
| Ovary | Adenocarcinoma | 1 (1%) | 961 | — | |
| Granulesa-theca cell tumor | 12 (12%) | 692 ± 52.0 | 1 (1%)** | 734 | |
| Hemangioma | 5 (5%) | 798 ± 71.8 | 6 (8%) | 668 ± 55.1 | |
| Cystadenoma | 2 (2%) | 878 ± 43.8 | 1 (1%) | 534 | |
| Mammary gland | Adenocarcinoma | 3 (3%) | 748 ± 163.4 | 4 (6%) | 480 ± 26.9 |
| Lung | Adenocarcinoma | 4 (4%) | 596 ± 54.8 | 7 (10%) | 480 ± 26.9 |
| Adenoma | 8 (8%) | 702 ± 72.5 | 4 (6%) | 749 ± 12.7 | |
| Liver | Hepatocellular carcinoma | 3 (3%) | 810 ± 20.6 | 6 (8%) | 664 ± 21.4*** |
| Hemangioendothelioma | — | 2 (3%) | 630 ± 35.6 | ||
| Haemangioma | 3 (3%) | 923 ± 53.8 | 2 (3%) | 628 | |
| Haematopoietic system | Malignant lymphoma | 5 (5%) | 711 ± 37.1 | 6 (8%) | 593 ± 40.1* |
| Thymoma | — | — | 1 (1%) | 208 | |
| Soft tissue | Subcutaneous angiosarcoma | 1 (1%) | 788 | — | |
| Hemangioendothelioma | 1 (1%) | 414 | 2 (3%) | 497 ± 103.1 | |
| Skin | Squamous-cell carcinoma | — | — | 1 (1%) | 392 |
| Colon | Adenocarcinoma | — | 1 (1%) | 393 | |
Significant in comparison with the PARP-1+/+: *: P < .05; **: P < .01; ***: P < .001.